Literature DB >> 9703278

Comparison of the cytotoxic activity of melphalan with L-prolyl-m-L-sarcolysyl-L-p-fluorophenylalanine in human tumour cell lines and primary cultures of tumour cells from patients.

R Larsson1, S Dhar, H Ehrsson, P Nygren, R Lewensohn.   

Abstract

m-L-sarcolysin (m-L-SL) is an isomer of melphalan (Mel) with the di(2-chloroethyl) amino group being substituted in the meta position of phenylalanine. By covalent conjugation of amino acids to m-L-SL, a peptide complex consisting of six m-L-SL-based oligopeptides known as peptichemio (PTC) was developed previously. In the present study, the cytotoxic activity pattern of the different oligopeptides of PTC was investigated in ten human tumour cell lines representing different mechanisms of cytotoxic drug resistance using the fluorometric microculture cytotoxicity assay (FMCA). In the cell line panel, L-prolyl-m-L-sarcolysyl-L-p-fluorophenylalanine (P2) was the most active oligopeptide, showing slightly lower mean IC50 values (2.6 vs 3.9 and 4.1 microg ml(-1)) than Mel and m-L-SL. The other five oligopeptides were less active than Mel. All active oligopeptides showed mechanistic similarity to Mel as judged by the correlation analysis of the cell line panel log IC50 values (R > or = 0.90), although P2 appeared to be less sensitive to GSH-mediated drug resistance. The relative activity of Mel and P2 was found to be related to degree of proliferation, P2 being more active towards low-proliferating cell lines. P2 and Mel were then further characterized in 49 fresh human tumour samples. In these samples P2 was considerably more active than Mel and showed a higher relative solid tumour activity (2.7 to 4.5-fold). However, the correlation of log IC50s between P2 and Mel in patient cells was high (R = 0.79), indicating a similar mechanism of action in this tumour model too. Cross-resistance with other standard drugs was lower for P2 than Mel. The results show that P2 is the most potent component of PTC and demonstrates a favourable activity profile compared with Mel. These data suggest that further investigation of P2 as a potential anti-tumour agent is warranted.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9703278      PMCID: PMC2063025          DOI: 10.1038/bjc.1998.494

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  34 in total

1.  Efficacy of peptide bound m-L-sarcolysin (peptichemio) on melphalan resistant human myeloma cells in vitro.

Authors:  R Lewensohn; J O Fernberg; H Ehrsson; G Merlini
Journal:  Med Oncol Tumor Pharmacother       Date:  1991

2.  Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26).

Authors:  M K Danks; J C Yalowich; W T Beck
Journal:  Cancer Res       Date:  1987-03-01       Impact factor: 12.701

3.  Peptichemio in the therapy of malignancies (phase-I-study). The evaluation committee.

Authors:  N Gingold; E Pittermann; A Stacher
Journal:  Int J Clin Pharmacol       Date:  1974-10

4.  Peptichemio, teniposide and high-dose dexamethasone: a new active combination for relapsing and refractory multiple myeloma. A pilot study.

Authors:  A Zaniboni; E Simoncini; P Marpicati; E Montini; G Rossi; G Marini
Journal:  Anticancer Res       Date:  1988 Jan-Feb       Impact factor: 2.480

5.  Increased cancericidal activity of PTT.119, a new synthetic bis-(2-chloroethyl)amino-L-phenylalanine derivative with carrier amino acids. I. In vitro cytotoxicity.

Authors:  M J Yagi; J G Bekesi; M D Daniel; J F Holland; A De Barbieri
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

6.  Peptichemio in pretreated patients with plasmacell neoplasms.

Authors:  A Paccagnella; L Salvagno; V Chiarion-Sileni; S Bolzonella; P De Besi; M Frizzarin; G L Pappagallo; V P Fosser; A Fornasiero; R Segati
Journal:  Eur J Cancer Clin Oncol       Date:  1986-09

7.  Peptichemio induction therapy in myelomatosis.

Authors:  G Merlini; P G Gobbi; A Riccardi; G Riva; C Sardi; S Perugini
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

8.  Peptichemio in pretreated patients with ovarian cancer.

Authors:  A Paccagnella; F Tredese; L Salvagno; A Brandes; V C Sileni; O Daniele; A Fornasiero; V Fosser; O Nicoletto; T Maggino
Journal:  Cancer Treat Rep       Date:  1985-01

9.  Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein.

Authors:  W S Dalton; B G Durie; D S Alberts; J H Gerlach; A E Cress
Journal:  Cancer Res       Date:  1986-10       Impact factor: 12.701

10.  Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin.

Authors:  S E Mirski; J H Gerlach; S P Cole
Journal:  Cancer Res       Date:  1987-05-15       Impact factor: 12.701

View more
  1 in total

1.  Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo.

Authors:  Joachim Gullbo; Elin Lindhagen; Saadia Bashir-Hassan; Marcus Tullberg; Hans Ehrsson; Rolf Lewensohn; Peter Nygren; Manuel De La Torre; Kristina Luthman; Rolf Larsson
Journal:  Invest New Drugs       Date:  2004-11       Impact factor: 3.850

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.